PRIME is a support program of the European Medicines Agency for medicinal products in development that have the potential to address a significant unmet medical need. The designation stands for “PRIority MEdicines.” PRIME accompanies development early on with intensive scientific and regulatory support, but it is not a type of marketing authorization and does not replace approval for placing a product on the market.
Access and Objectives
PRIME is intended for medicinal products that are not yet authorized in the European Union. For admission, it must be plausible that the product can address a significant unmet medical need. Access is requested during development. Small and medium-sized enterprises as well as academic or non-profit applicants may also be introduced to the program through an early access status if they provide suitable proof of efficacy in the form of a proof of principle.
The program aims to improve the development of evidence so that the data of a subsequent marketing authorization application are suitable for assessment. It does not automatically shorten the regulatory requirements for quality, safety, or efficacy. Rather, it is intended to clarify early on which studies, quality data, consultation steps, and regulatory decisions are necessary for a viable development program.
Support During Development
For medicinal products with PRIME access, the EMA appoints early on a rapporteur from the Committee for Medicinal Products for Human Use or, for advanced therapy medicinal products, from the relevant committee. In addition, a PRIME Scientific Coordinator and a kick-off meeting with a multidisciplinary expert team are provided. This structure facilitates coordination on the overall development plan, future scientific advice, and the regulatory strategy.
PRIME thus creates a framework for recurring, development-accompanying discussions. It can strengthen the quality of evidence planning and the preparation of a subsequent dossier, but does not grant a positive decision in advance. The subsequent marketing authorization application will continue to be reviewed according to the standards applicable to the centralized procedure. The review of GCP, GMP, and pharmacovigilance aspects also remains unaffected.
Distinction from Accelerated Assessment and Breakthrough Therapy Designation
PRIME must be distinguished from accelerated assessment. PRIME is a development program prior to submission of the marketing authorization application. Accelerated assessment, on the other hand, concerns the duration of the CHMP evaluation of an already submitted application in the centralized procedure. A PRIME product may be considered for accelerated assessment at the time of application; however, this is not an automatic consequence and not a guarantee of authorization.
The US Breakthrough Therapy Designation is also not equivalent to PRIME. It is an FDA designation for medicinal products for the treatment of serious conditions when preliminary clinical evidence indicates a substantial improvement over available therapies on a clinically significant endpoint. PRIME is the European program with its own access criterion, its own governance, and its own regulatory framework. Both programs can provide intensive development support, but they are legally and institutionally distinct.
Access to PRIME is not granted solely on the basis of the medical severity of a condition. The EMA expects a justification as to why the specific development product can significantly address an unmet need. During development, the status is continuously measured against its purpose; it replaces neither the generation of robust data nor the regular applications for scientific advice. Early appointment of regulatory contacts can be particularly valuable when multiple complex evidence streams from clinical development, quality, and risk management need to be integrated.
Careful documentation of development assumptions facilitates demonstrating continuity between PRIME support, scientific advice, and the subsequent marketing authorization dossier. This is especially true for changes to key study decisions.
The decision on access is therefore based on the individual product and its documented development perspective, not on a general disease category.
Relevance for clinical trials
For clinical trials, PRIME primarily means early requirements for evidence planning. Development programs must justify how population, comparator, endpoints, duration of follow-up, and safety data will support a subsequent benefit-risk assessment. The benefit of early interaction depends on whether insights from advice and rapporteur discussions are translated into protocols, analysis planning, quality strategy, and operational feasibility.
Full-service CROs such as Mediconomics support preparation for PRIME through development planning, study design, biostatistics, medical writing, and regulatory affairs. Specific services include consolidation of preliminary findings, structuring of briefing documents, preparation of scientific advice, documentation of regulatory feedback, and translation of agreed measures into study protocols, data management plans, and realistic project timelines.
Frequently Asked Questions (FAQ)
Is PRIME a marketing authorization?
No. PRIME is a support program during development and not an approval for placing a product on the market.
Does every PRIME medicinal product receive accelerated assessment?
No. PRIME may indicate subsequent eligibility for accelerated assessment, but the decision is made separately.
Is PRIME the European equivalent of Breakthrough Therapy Designation?
The programs pursue similar acceleration objectives but differ in legal framework, access criteria, and responsible authority.
Regulatory References
- Regulation (EC) No 726/2004, Article 57 – describes the tasks of the EMA in scientific advice.
- Regulation (EC) No 726/2004, Article 14(9) – provides the basis for accelerated assessment.
- EMA guideline on PRIME – explains access, support, and development accompaniment.
- US Food, Drug, and Cosmetic Act, Section 506(a) – forms the basis of the FDA Breakthrough Therapy Designation.
